ライフサイエンスコーパス: fibroadenoma

1 In one mass, repeat LCNB findings showed a fibroadenoma.

2 .91, 1.00) for triple-negative cancer versus fibroadenoma.

3 s between triple-negative cancers and benign fibroadenomas.

4 med to noninvasively coagulate benign breast fibroadenomas.

5 f 5 of 11 infiltrating carcinomas and 2 of 6 fibroadenomas.

6 ypes with mean ADCs above the threshold were fibroadenoma ([1.94 +/- 0.38 {standard deviation}] x 10(

7 y or aspiration of all lesions, revealing 15 fibroadenomas, 12 carcinomas, six fibrocystic nodules, a

8 odel was used to correctly classify 10 of 38 fibroadenomas (26%) and three of seven stromal fibroses

9 oxyestradiol formation in adenocarcinoma and fibroadenoma, 3.8 and 3.7, respectively).

10 were identified within nine of 14 enhancing fibroadenomas (64%) and appeared to correlate with colla

11 hape was lobular, oval, or round in 19 of 23 fibroadenomas (83%).

12 ed 5-10-fold over benign conditions, such as fibroadenoma and fibrocystic disease.

13 Fibroepithelial lesions include fibroadenoma and phyllodes tumor, which can be difficult

14 Seventy-three percent of fibroadenomas and 56% of solid benign lesions could be d

15 ly observed MED12 and RARA mutations in both fibroadenomas and phyllodes tumors, emphasizing the impo

16 ED12 mutations have been frequently found in fibroadenomas and phyllodes tumors, the landscapes of ge

17 apillomas, sclerosing adenosis, radial scar, fibroadenoma, and areas of atypical ductal hyperplasia.

18 ish normal tissue, fibrocystic change (FCC), fibroadenoma, and breast cancer, in the absence and pres

19 nd in human breast cancer cell lines, breast fibroadenoma, and ductal adenocarcinomas.

20 n breast tissue (normal, fibrocystic change, fibroadenoma, and infiltrating carcinoma) from 58 patien

21 There were 25 cancers, 38 fibroadenomas, and 23 other benign lesions.

22 The imaging findings were suggestive of fibroadenomas, and biopsy results were used to confirm t

23 The development and persistence of fibroadenomas are dependent on the presence of ovarian h

24 Fibroadenomas are the most common breast tumors in women

25 four of six benign papillomas and one of two fibroadenomas as circumscribed, enhancing subareolar mas

26 Targeted sequencing of an additional 90 fibroadenomas confirmed highly frequent MED12 exon 2 mut

27 ions include lobular and ductal hyperplasia, fibroadenoma, cystic expansions, and papillary adenomas.

28 Fibroadenomas demonstrate marked histopathologic variabi

29 Fibroadenomas demonstrated high T2 signal intensity with

30 vasive breast cancers, 7 mastopathias, and 2 fibroadenomas demonstrates that a highly sensitive, spec

31 patients compared with that in patients with fibroadenoma (FIBma) or healthy individuals, and the pos

32 ted for age, menopausal status, soy protein, fibroadenoma history, family breast cancer, physical act

33 iated with the presence of cancer and breast fibroadenoma in a given family ( P = 0.024).

34 iation of PTEN mutation and cancer or breast fibroadenoma in any given CS, BRR or BRR/CS overlap fami

35 Twenty-three fibroadenomas in 21 patients (aged 23-66 years) examined

36 Eleven fibroadenomas in nine patients under local anesthesia we

37 x patients and complex cystic masses (myxoid fibroadenomas) in one patient.

38 Cryotherapy of fibroadenomas is a safe, effective, and virtually painle

39 ons, 20% had dysplastic lesions, and 15% had fibroadenoma lesions.

40 pear to reflect intrinsic growth patterns of fibroadenomas, may provide a more reliable basis for dis

41 The fibroadenoma MED12 mutation spectrum is nearly identical

42 capture microdissection, we show that MED12 fibroadenoma mutations are present in stromal but not ep

43 ositive (n = 25), HER2-positive (n = 18), or fibroadenoma (n = 12) lesions.

44 ich produced neoplastic phenotype, including fibroadenomas of the breast and salivary gland adenomas.

45 iated mesenchymal tumors, including lipomas, fibroadenomas of the breast, salivary gland adenomas, an

46 iometric properties resembling either benign fibroadenoma or invasive carcinoma samples.

47 g appearances that probably represent myxoid fibroadenomas or ductal adenomas.

48 o specific categories of normal tissue, FCC, fibroadenoma, or breast cancer (with and without microca

49 noma (IDC) but not ductal carcinoma in situ, fibroadenoma, or normal breast tissues.

50 were statistically significantly darker than fibroadenomas (P < .005) and substantially larger on the

51 Power Doppler US depicted no vessels in 21 fibroadenomas, peripheral vessels in 15, and penetrating

52 epared from human mammary adenocarcinoma and fibroadenoma predominantly catalyze the metabolic 4-hydr

53 Based on 1,507 women who developed fibroadenoma, relative risks and trends in risk were est

54 ion profiling of MED12-mutated and wild-type fibroadenomas revealed that MED12 mutations are associat

55 gery, the diagnosis of cyclosporin A-induced fibroadenomas should be considered.

56 age findings of normal breast tissue, benign fibroadenomas (six of six lesions), and malignant lesion

57 tice of breast self-examination detects some fibroadenomas that would otherwise not be detected.

58 ectrum of pathological entities, from benign fibroadenomas to malignant phyllodes tumors.

59 6%) of the 44 masses were cysts; three (7%), fibroadenomas; two (4%), infiltrating ductal carcinomas;

60 The average pretreatment fibroadenoma volume of 4.2 cm(3)+/- 4.7 (standard deviat

61 The risk of a diagnosis of fibroadenoma was elevated in women who received instruct

62 The risk of fibroadenoma was highest in women under 35 years of age,

63 Risk factors for fibroadenoma were investigated in a cohort of 265,402 fe

64 Fibrocystic changes and benign fibroadenomas were identified.

65 Forty-two biopsy-confirmed fibroadenomas were treated in 29 patients (mean age, 27

66 tinguishable from normal tissue in all three fibroadenomas, were indistinguishable from normal findin

67 alcifications was decreased in size, and one fibroadenoma with ALH was stable.

68 , a papilloma with adjacent LCIS; and one, a fibroadenoma with LCIS in it.

69 y using a 2.4-mm cryoprobe inserted into the fibroadenoma with US guidance.

70 Exome sequencing of eight fibroadenomas with matching whole-blood samples revealed